Pauken, Kristen E.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,434

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,664

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,348

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 1,216

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion

Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 868

Resident memory CD8 T cells trigger protective innate and adaptive immune responses

Schenkel, J. M., Fraser, K. A., Beura, L. K., Pauken, K. E., Vezys, V., & Masopust, D. (2014) · Science

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 731

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 280

Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity

Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 237

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 97

Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade

Rowe, J. H., Elia, I., Shahid, O., Gaudiano, E. F., Sifnugel, N. E., Johnson, S., Reynolds, A. G., Fung, M. E., Joshi, S., LaFleur, M. W., et al. (2023) · Cancer Discovery

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 59